Risovalisib Mesylate

N/A

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NameRisovalisib Mesylate
Drug Alias Name瑞索利塞海泽欣CYH-33HH-CYH33
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPhosphatidylinositol 3 kinase alpha inhibitors
TargetsPhosphatidylinositol 3 kinase alpha
Therapy Area/IndicationsOvarian Clear Cell CarcinomaSolid tumoursPIK3CA-Related Overgrowth Spectrum +[16] 
Global Approved IndicationsOvarian Clear Cell Carcinoma
Approved Indications in ChinaN/A
Original Approved Country/TerritoryJapan
Original Approved Date2026/03/23
Country/TerritoryUnited StatesAustraliaMainland China +[4] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesShangHai HaiHe Biopharma Co LtdShanghai Institute Of Materia Medica, Chinese Academy Of Sciences
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesTaiho Pharmaceutical Co LtdHaihe Biopharma (HK) LtdShanghai Institute Of Materia Medica, Chinese Academy Of Sciences +[4] 
Inactive CompaniesN/A
Active IndicationsOvarian Clear Cell CarcinomaSolid tumoursPIK3CA-Related Overgrowth Spectrum +[13] 
Inactive IndicationsProstatic NeoplasmsEndometrial NeoplasmsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A